Bristol Platinol patent extends to 2012 following Oct. 8 cisplatin patent issuance, 26 years after filing.
Executive Summary
BRISTOL PLATINOL (CISPLATIN) BASIC PATENT RUNS TO MAY 8, 2012 following the issuance of U.S. Patent No. 5,562,925 for the compound on Oct. 8. The patent was granted by the Patent & Trademark Office to Tucson, Ariz.-based Research Corporation Technologies, which licenses the patent to Bristol. Cisplatin is already protected by a use patent which expires Dec. 4.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth